Adrian Alonso Ruiz

Dr. Adrian Alonso Ruiz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMarcela Fogaça Vieira
Marcela Fogaça Vieira
ISIulia Slovenski
Iulia Slovenski
KLKaitlin Large
Kaitlin Large
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
SMSuerie Moon
Suerie Moon
Alternative innovation models have emerged to address failures of the traditional pharmaceutical system, particularly for diseases where market incentives do not attract sufficient research and development efforts. However, the feasibility of such models for diseases with significant markets is not well-established. This article analyses the development of a novel drug (ravidasvir) for the treatment of hepatitis C, a highly profitable market. Data from qualitative research methods, including literature reviews and semi-structured interviews, was analyzed using a novel conceptual framework focusing on actors, resources, organizational practices, and outcomes. Dissimilar to other projects, ravidasvir did not involve any major pharmaceutical companies. Rather, it leveraged the capacities of actors less traditionally involved in the development of novel medicines by constructing a collaborative network of private and public partners from low- and middle-income countries with a shared goal. The collaboration was successful in developing a highly effective, easy-to-use, and affordable medicine and contributed significantly to capacity-strengthening. However, the case also highlighted that strategic behavior by competing for-profit firms could pose significant challenges and that changing external conditions reduced the potential public health impact of the drug. Lessons from ravidasvir can inform future efforts to develop alternative innovation models for therapeutic areas with significant commercial interest.

26 March 2024 in Globalization and Health
Verified
Journal Article
Open access
PDF file
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
ABAnna Bezruki
Anna Bezruki
ESErika Shinabargar
Erika Shinabargar
KLKaitlin Large
Kaitlin Large
MVMarcela Vieira
Marcela Vieira
SMSuerie Moon
Suerie Moon
Background: Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers’ practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access. Results: Using data on R&D investments, regulatory approvals, manufacturing and purchase agreements, and vaccine deliveries, we identified six distinct innovation models that apply across the 14 COVID-19 vaccines with more international presence from 2020–2022. “Western Early Arrivers” Pfizer/BioNTech and Moderna supplied the largest volumes quickly and prioritized high-income countries (HICs) from registration to vaccine delivery. “Western Latecomers” Janssen and Novavax supplied intermediate volumes later, also prioritizing HICs but with a greater proportion to L&MICs. “Major Chinese Developers” Sinopharm and Sinovac supplied intermediate volumes early, primarily to middle-income countries (MICs). “Russian Developer” Gamaleya completed development early but ultimately supplied small volumes, primarily to middle-income countries (MICs). “Cosmopolitan Developer” Oxford/AstraZeneca supplied large volumes early to HICs and MICs at the lowest prices. Finally, “Small MIC Developers” CanSino, Bharat Biotech, Medigen, Finlay Institute and the Center for Genetic Engineering and Biotechnology (CGEB), exported relatively small volumes to a few MICs. Low-income countries (LICs) were not targeted by any developer, and received far fewer doses, later, than any other income group. Almost all developers received public funding and other forms of support, but we found little evidence that such support was leveraged to expand global access. Conclusions: Each of the six innovation models has different implications for which countries get access to which vaccines, how quickly, and at which prices. Each offers different strengths and weaknesses for achieving equitable access. Our findings also suggest that Western firms had the greatest capacity to develop and deliver vaccines quickly during the pandemic, but such capacity is rapidly becoming more globally distributed with MICs playing a significant role, especially in supplying other MICs. Given the critical role of public support in enabling pandemic vaccine development and supply, governments have both the capacity and responsibility to craft international rules that will make responses to future pandemics more equitable and effective.

13 November 2023 in F1000Research
Verified
Journal Article
Open access
PDF file
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
KLKaitlin Large
Kaitlin Large
SMSuerie Moon
Suerie Moon
MVMarcela Fogaça Vieira
Marcela Fogaça Vieira
This article aims to synthesize the existing literature on the implementation of public policies to incentivize the development of treatments for rare diseases, (diseases with very low prevalence and therefore with low commercial interest) otherwise known as orphan drugs. The implementation of these incentives in the United States (US), Japan, and in the European Union (EU) seems to be related to a substantial increase in treatments for these diseases, and has influenced the way the pharmaceutical research & development (R&D) system operates beyond this policy area. Despite the success of the Orphan Drug model, the academic literature also highlights the negative implications that these public policies have on affordability and access to orphan drugs, as well as on the prioritization of certain disease rare areas over others. The synthesis focuses mostly on the United States’ Orphan Drug Act (ODA) as a model for subsequent policies in other regions and countries. It starts with a historical overview of the creation of the term “rare diseases”, continues with a summary of the evidence available on the US ODA’s positive and negative impacts, and provides a summary of the different proposals to reform these incentives in light of the negative outcomes described. Finally, it describes some key aspects of the Japanese and European policies, as well as some of the challenges captured in the literature related to their impact in Low- and Middle-Income Countries (LMICs).

17 January 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
KLKaitlin Large
Kaitlin Large
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
ISIulia Slovenski
Iulia Slovenski
MVMarcela Vieira
Marcela Vieira
SMSuerie Moon
Suerie Moon
Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas. The development of OCVs was made possible through an alternative innovation model, which sustained innovation across multiple generations of the product for more than three decades. To examine how this alternative innovation model worked, we conducted 18 semi-structured interviews with key stakeholders related to the development of several OCVs, including “Dukoral”, “Shanchol”, and “Euvichol-Plus”, as well as additional cholera vaccines currently under development. Interview data was analyzed thematically according to the resources used by organizations (including funding, knowledge, relationships, and manufacturing), and the practices they implemented during each stage of the R&D process (including knowledge management and intellectual property strategies, approaches to transparency, and global access strategies). Next, we created participatory network maps to illustrate the structure of the relationships between stakeholders and how these evolved over time. We found that a core group of stakeholders were able to influence policies to promote the use of OCVs, and successfully develop, finance, and obtain WHO Prequalification for safe, effective, and affordable OCVs for global procurement and distribution. The evolution of OCVs demonstrates how a collaborative network innovation model can successfully develop new pharmaceutical products that are affordable and well-suited for use in context. This model could be applied to other areas of pharmaceutical innovation, such as pandemic preparedness, for more equitable outcomes for global public health.

16 January 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
SMSuerie Moon
Suerie Moon
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
MVMarcela Fogaça Vieira
Marcela Fogaça Vieira
KLKaitlin Large
Kaitlin Large
ISIulia Slovenski
Iulia Slovenski
The current mainstream pharmaceutical innovation system (PIS) is driven by the market-based logic of charging the highest prices societies will bear. Outcomes include unaffordable medicines, restricted access and pressure on health budgets. How can the innovation system change to deliver fairly-priced medicines? We inductively developed a novel conceptual framework of the PIS as a complex adaptive system (CAS) analogous to a forest. We constructed a database of 140 pharmaceutical innovation initiatives that sought to address global public interest objectives such as fair pricing or missing innovation. We found a critical mass of initiatives clustered around four areas: pandemic preparedness, neglected diseases, rare diseases and antibiotics, which we conceptualised as niches within the ecosystem. We reviewed the literature on how each niche had emerged and evolved, conducted interviews, and organised workshops with experts on each niche. Finally, we identified from the literature an initial list of ‘levers’ of change in the PIS, supplemented them with additional levers found in each niche, then compared across niches. We found that actors created niches in the broader system by purposefully problematising an issue, then pulling on one or more of three levers: mobilising new resources, changing the roles of or creating new actors, and/or changing societal norms or legal rules. A wide range of actors – including governments, funders, R&D practitioners, or civil society groups – could pull these levers, and the order in which they were pulled was not fixed, consistent with a CAS. Parts of the vast pharmaceutical innovation system have changed to deliver more affordable medicines by design. Such change has occurred largely within specialised niches, responding to evolving societal norms about the purpose of pharmaceutical innovation. Actors can achieve larger-scale change by further expanding and/or solidifying these niches through changes to resources, actor roles, norms and rules.

10 April 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
ESErika Shinabargar
Erika Shinabargar
ISIulia Slovenski
Iulia Slovenski
KLKaitlin Large
Kaitlin Large
MVMarcela Vieira
Marcela Vieira
SMSuerie Moon
Suerie Moon
Background: Increasing costs of drugs for rare diseases have raised concerns about health systems’ sustainability and equitable access to these therapies. Newer and highly effective orphan drugs, such as Chimeric Antigen Receptor T-Cell (CAR-T) therapies, highlight the need for alternative innovation models that can offer greater affordability and accessibility. This case study examines Hospital Clínic Barcelona’s (HCB) alternative innovation model to develop ARI-0001 (varnimcabtagene autoleucel), a novel CAR-T therapy for certain forms of leukemia, at a price two-thirds lower than comparable therapies from the pharmaceutical industry. Methods: We conducted background research, and performed twenty-one semi-structured interviews with HCB staff, representatives of regional Health Departments, the Spanish Ministry of Health and regulatory agency, academics, civil society and patient groups. We used a framework drawing on concepts from complex adaptive systems, incorporating the resources used (i.e., funding, knowledge, and manufacturing capacity), the practices implemented (i.e., knowledge management, access practices and transparency), and the rules and norms that shaped HCB’s interactions with other actors in the system. We then identified the concept of institutional logics as well-suited to explain how HCB’s model overcame various barriers. Results: HCB’s model builds from three competing institutional logics – healthcare, academic and industrial – while also addressing each logic’s weaknesses. The healthcare logic shaped HCB’s affordable pricing of ARI-0001, but also posed organizational challenges. The academic logic drove HCB’s willingness to share knowledge and technology with peers, but posed barriers to fund late-stage clinical trials and regulatory processes. Lastly, HCB adopted an industrial logic by identifying in-house regulatory expertise and developing partnerships for production. The hospital exemption clause, a European regulatory pathway that allows hospitals to develop and produce treatments under certain conditions, allowed HCB to span the boundaries of the three competing logics. Conclusions: Our findings underscore the potential of academic hospitals to develop more affordable advanced therapies, the importance of conducive regulatory frameworks, and the challenges that academic hospitals face to expand this model. Through increased regulatory and financial support to academic hospitals, strengthened coordination, and public funding with requirements for access, this model could achieve innovation with affordability in a cutting-edge technological area.